A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2022
This article has no abstract
Epistemonikos ID: 1e270f3fb131e5766c2c8f405cdc47578fad9650
First added on: Mar 21, 2025